Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 2/20 | 0.62 |
| ▸ | IDO1 | P14902 | 3/20 | 0.50 |
| ▸ | NOS1 | P29475 | 4/20 | 0.49 |
| ▸ | METAP2 | P50579 | 1/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
| ▸ | DHPS | P49366 | 1/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | MET | P08581 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2627058 | 0.84 | AXL (0.68) | AXLIDO1NOS1METAP2JAK2 | |
| SCHEMBL12683720 | 0.77 | AXL (1.00) | AXLIDO1NOS1METAP2JAK2 | |
| SCHEMBL20182527 | 0.76 | AXL (0.50) | AXLIDO1NOS1METAP2JAK2 | |
| SCHEMBL21938210 | 0.75 | IDO1 (0.38) | AXLIDO1NOS1METAP2TRPA1 | |
| SCHEMBL22430426 | 0.75 | NOS1 (0.47) | AXLIDO1NOS1TRPA1HSP90AA1 | |
| SCHEMBL6531155 | 0.74 | AXL (0.55) | AXLIDO1NOS1METAP2JAK2 | |
| SCHEMBL2633084 | 0.73 | IDO1 (0.55) | AXLIDO1NOS1METAP2JAK2 | |
| SCHEMBL26825623 | 0.73 | AXL (0.43) | AXLIDO1NOS1METAP2JAK2 | |
| SCHEMBL20259741 | 0.72 | AXL (0.46) | AXLIDO1NOS1METAP2JAK2 | |
| SCHEMBL21334557 | 0.72 | IDO1 (0.50) | AXLIDO1NOS1METAP2JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220211855-A1 | THERAPEUTIC CONJUGATES | TOTUS MEDICINES INC. | 2022-07-07 | — | — | US | disclosed |
| US-20220127265-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2022-04-28 | — | — | US | disclosed |
| EP-2629771-B1 | USE OF PI3K INHIBITORS FOR THE TREATMENT OF OBESITY, STEATOSIS AND AGEING | FUNDACION CENTRO NAC DE INVESTIGACIONES ONCOLOGICAS CARLOS III (ES) | 2018-08-08 | — | — | EP | disclosed |
| US-9993554-B2 | Use of P13K Inhibitors for the Treatment of Obesity, Steatosis and ageing | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2018-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220211855-A1 | THERAPEUTIC CONJUGATES | CD47, CD44, EPCAM | AXL 3112/4885IDO1 4317/4885NOS1 4722/4885 |
| US-20220127265-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | EP300, HDAC1, CREBBP | AXL 4614/4885IDO1 3724/4885NOS1 4351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.